Prediction of the binding mode and resistance profile for a dual-target pyrrolyl diketo acid scaffold against HIV-1 integrase and reverse-transcriptase-associated ribonuclease H.

The rapid emergence of drug-resistant variants is one of the most common causes of highly active antiretroviral therapeutic (HAART) failure in patients infected with HIV-1. Compared with the existing HAART, the recently developed pyrrolyl diketo acid scaffold targeting both HIV-1 integrase (IN) and reverse transcriptase-associated ribonuclease H (RNase H) is an efficient approach to counteract the failure of anti-HIV treatment due to drug resistance. However, the binding mode and potential resistance profile of these inhibitors with important mechanistic principles remain poorly understood. To address this issue, an integrated computational method was employed to investigate the binding mode of inhibitor JMC6F with HIV-1 IN and RNase H. By using per-residue binding free energy decomposition analysis, the following residues: Asp64, Thr66, Leu68, Asp116, Tyr143, Gln148 and Glu152 in IN, Asp443, Glu478, Trp536, Lys541 and Asp549 in RNase H were identified as key residues for JMC6F binding. And then computational alanine scanning was carried to further verify the key residues. Moreover, the resistance profile of the currently known major mutations in HIV-1 IN and 2 mutations in RNase H against JMC6F was predicted by in silico mutagenesis studies. The results demonstrated that only three mutations in HIV-1 IN (Y143C, Q148R and N155H) and two mutations in HIV-1 RNase H (Y501R and Y501W) resulted in a reduction of JMC6F potency, thus indicating their potential role in providing resistance to JMC6F. These data provided important insights into the binding mode and resistance profile of the inhibitors with a pyrrolyl diketo acid scaffold in HIV-1 IN and RNase H, which would be helpful for the development of more effective dual HIV-1 IN and RNase H inhibitors.

[1]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[2]  Xiaowu Chen,et al.  Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. , 2010, Antiviral research.

[3]  Feng Zhu,et al.  Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder. , 2018, Physical chemistry chemical physics : PCCP.

[4]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[5]  E. Tramontano,et al.  Past and Future. Current Drugs Targeting HIV-1 Integrase and Reverse Transcriptase-Associated Ribonuclease H Activity: Single and Dual Active Site Inhibitors , 2014, Antiviral chemistry & chemotherapy.

[6]  Y. Qiao,et al.  Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis , 2017, The lancet. HIV.

[7]  Martti T Tammi,et al.  What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets , 2009, Journal of Pharmacology and Experimental Therapeutics.

[8]  Vasanthanathan Poongavanam,et al.  Dual mechanism of HIV-1 integrase and RNase H inhibition by diketo derivatives – a computational study , 2014 .

[9]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[10]  Ricky Chachra,et al.  Origins of Resistance Conferred by the R292K Neuraminidase Mutation via Molecular Dynamics and Free Energy Calculations. , 2008, Journal of chemical theory and computation.

[11]  N. Srinivas.  Antiretroviral Therapy With Efavirenz in HIV‐Infected Pregnant Women: Understanding the Possible Mechanisms for Drug–Drug Interaction , 2018, Clinical pharmacology and therapeutics.

[12]  Feng Zhu,et al.  Comparison of computational model and X-ray crystal structure of human serotonin transporter: potential application for the pharmacology of human monoamine transporters , 2017 .

[13]  Yuntao Wu,et al.  HIV-1 gene expression: lessons from provirus and non-integrated DNA , 2004, Retrovirology.

[14]  Lin Tao,et al.  Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting , 2011, Proceedings of the National Academy of Sciences.

[15]  Xiaojie Jin,et al.  Exploring the Molecular Mechanism of Cross-Resistance to HIV-1 Integrase Strand Transfer Inhibitors by Molecular Dynamics Simulation and Residue Interaction Network Analysis , 2013, J. Chem. Inf. Model..

[16]  Feng Zhu,et al.  Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study , 2016, Scientific Reports.

[17]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[18]  Lu Huang,et al.  Update of TTD: Therapeutic Target Database , 2009, Nucleic Acids Res..

[19]  Barry Honig,et al.  Extending the Applicability of the Nonlinear Poisson−Boltzmann Equation: Multiple Dielectric Constants and Multivalent Ions† , 2001 .

[20]  M. Mouroux,et al.  Resistance profile and cross‐resistance of HIV‐1 among patients failing a non‐nucleoside reverse transcriptase inhibitor‐containing regimen * , 2001, Journal of medical virology.

[21]  Zhen Tian,et al.  Structural insights into Cydia pomonella pheromone binding protein 2 mediated prediction of potentially active semiochemicals , 2016, Scientific Reports.

[22]  R. Ghirlando,et al.  Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome , 2017, Science.

[23]  S. Sarafianos,et al.  Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H. , 2016, Journal of medicinal chemistry.

[24]  Guangdi Li,et al.  Approved Antiviral Drugs over the Past 50 Years , 2016, Clinical Microbiology Reviews.

[25]  V. Calvez,et al.  Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. , 2015, The Journal of antimicrobial chemotherapy.

[26]  T. Hawkins.  Understanding and managing the adverse effects of antiretroviral therapy. , 2010, Antiviral research.

[27]  Weiwei Xue,et al.  The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective , 2016, PloS one.

[28]  Huanxiang Liu,et al.  Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. , 2012, Antiviral research.

[29]  Amy S. Espeseth,et al.  HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Y. Pommier,et al.  Madurahydroxylactone Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and RNase H , 2007, Antimicrobial Agents and Chemotherapy.

[31]  Wei Jiang,et al.  CHARMM-GUI Ligand Binder for Absolute Binding Free Energy Calculations and Its Application , 2013, J. Chem. Inf. Model..

[32]  Matthew J. Gonzales,et al.  Distribution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Mutation Patterns in 4,183 Persons Undergoing Genotypic Resistance Testing , 2004, Antimicrobial Agents and Chemotherapy.

[33]  Feng Zhu,et al.  Clinical Success of Drug Targets Prospectively Predicted by In Silico Study. , 2017, Trends in pharmacological sciences.

[34]  Ray Luo,et al.  Recent Developments and Applications of the MMPBSA Method , 2018, Front. Mol. Biosci..

[35]  K. Sharp,et al.  Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models , 1994 .

[36]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[37]  A. Yan,et al.  Targeting HIV-1 integrase with strand transfer inhibitors. , 2015, Drug discovery today.

[38]  P. Kollman,et al.  Computational Alanine Scanning To Probe Protein−Protein Interactions: A Novel Approach To Evaluate Binding Free Energies , 1999 .

[39]  Daniel Cappel,et al.  Relative Binding Free Energy Calculations Applied to Protein Homology Models , 2016, J. Chem. Inf. Model..

[40]  Feng Zhu,et al.  Performance Evaluation and Online Realization of Data-driven Normalization Methods Used in LC/MS based Untargeted Metabolomics Analysis , 2016, Scientific Reports.

[41]  A. Somasunderam,et al.  Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial , 2016, PLoS pathogens.

[42]  A. Engelman,et al.  Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.

[43]  Shantenu Jha,et al.  Computing Clinically Relevant Binding Free Energies of HIV-1 Protease Inhibitors , 2014, Journal of chemical theory and computation.

[44]  Youyong Li,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. , 2014, Physical chemistry chemical physics : PCCP.

[45]  Feng Zhu,et al.  Differentiating Physicochemical Properties between Addictive and Nonaddictive ADHD Drugs Revealed by Molecular Dynamics Simulation Studies. , 2017, ACS chemical neuroscience.

[46]  Qin Xu,et al.  Impact of Resistance Mutations on Inhibitor Binding to HIV-1 Integrase , 2013, J. Chem. Inf. Model..

[47]  R. Nussinov,et al.  Hot regions in protein--protein interactions: the organization and contribution of structurally conserved hot spot residues. , 2005, Journal of molecular biology.

[48]  Tingting Fu,et al.  Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics , 2017, Nucleic Acids Res..

[49]  Huanxiang Liu,et al.  Understanding the effect of drug-resistant mutations of HIV-1 intasome on raltegravir action through molecular modeling study. , 2012, Molecular bioSystems.

[50]  Jack A. Tuszynski,et al.  Detailed Computational Study of the Active Site of the Hepatitis C Viral RNA Polymerase to Aid Novel Drug Design , 2013, J. Chem. Inf. Model..

[51]  Yves Pommier,et al.  Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572) , 2011, Molecular Pharmacology.

[52]  M. Wainberg,et al.  Novel therapeutic strategies targeting HIV integrase , 2012, BMC Medicine.

[53]  Ulf Ryde,et al.  Convergence of QM/MM free-energy perturbations based on molecular-mechanics or semiempirical simulations. , 2012, Physical chemistry chemical physics : PCCP.

[54]  Feng Xu,et al.  Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information , 2015, Nucleic Acids Res..

[55]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[56]  E. Novellino,et al.  New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H. , 2016, Antiviral research.

[57]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[58]  Ge-Fei Hao,et al.  Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem. , 2012, Drug discovery today.

[59]  D. Davies,et al.  Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Feng Zhu,et al.  Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks , 2016, BioMed research international.

[61]  Christopher L. Daniels,et al.  Structural Basis for the Inhibition of RNase H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed Inhibitors , 2010, Journal of Virology.

[62]  E. Arnold,et al.  Structures of HIV-1 RT-RNA/DNA ternary complexes with dATP and nevirapine reveal conformational flexibility of RNA/DNA: insights into requirements for RNase H cleavage , 2014, Nucleic acids research.

[63]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[64]  Bo Li,et al.  NOREVA: normalization and evaluation of MS-based metabolomics data , 2017, Nucleic Acids Res..

[65]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[66]  Xiao Hua Ma,et al.  Drug Discovery Prospect from Untapped Species: Indications from Approved Natural Product Drugs , 2012, PloS one.

[67]  E. Tramontano,et al.  Molecular aspects of the RT/drug interactions. Perspective of dual inhibitors. , 2013, Current pharmaceutical design.

[68]  Youyong Li,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models. , 2013, The journal of physical chemistry. B.

[69]  Feng Zhu,et al.  Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder. , 2017, Physical chemistry chemical physics : PCCP.

[70]  K. White,et al.  Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial , 2017, The Lancet.

[71]  K. Schweimer,et al.  Inhibition of Foamy Virus Reverse Transcriptase by Human Immunodeficiency Virus Type 1 RNase H Inhibitors , 2014, Antimicrobial Agents and Chemotherapy.

[72]  Lin Li,et al.  Theoretical Studies on the Susceptibility of Oseltamivir against Variants of 2009 A/H1N1 Influenza Neuraminidase , 2012, J. Chem. Inf. Model..

[73]  M. Wainberg,et al.  Evolution of HIV integrase resistance mutations , 2012, Current opinion in infectious diseases.

[74]  Feng Zhu,et al.  Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD. , 2017, Biochimica et biophysica acta. General subjects.

[75]  Jennifer L. Knight,et al.  OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. , 2016, Journal of chemical theory and computation.

[76]  P. Ziprin,et al.  Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates , 2016, AIDS.

[77]  Feng Zhu,et al.  Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. , 2016, Physical chemistry chemical physics : PCCP.

[78]  Hongli Liu,et al.  Molecular dynamics simulations and novel drug discovery , 2018, Expert opinion on drug discovery.

[79]  A. Engelman,et al.  Structure-based modeling of the functional HIV-1 intasome and its inhibition , 2010, Proceedings of the National Academy of Sciences.

[80]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[81]  C. Isel,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Reverse Transcriptase, RNase H, and Integrase Activities by Hydroxytropolones , 2005, Antimicrobial Agents and Chemotherapy.

[82]  Martti T. Tammi,et al.  Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting , 2008 .

[83]  O. Uthman,et al.  Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. , 2017, The lancet. HIV.

[84]  Feng Zhu,et al.  Assessing the Performances of Protein Function Prediction Algorithms from the Perspectives of Identification Accuracy and False Discovery Rate , 2018, International journal of molecular sciences.

[85]  Yuzong Chen,et al.  What Contributes to Serotonin-Norepinephrine Reuptake Inhibitors' Dual-Targeting Mechanism? The Key Role of Transmembrane Domain 6 in Human Serotonin and Norepinephrine Transporters Revealed by Molecular Dynamics Simulation. , 2018, ACS chemical neuroscience.

[86]  Cheng Zhang,et al.  Nature's contribution to today's pharmacopeia , 2014, Nature Biotechnology.

[87]  R. D. Santo.  Diketo Acids Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain , 2011 .

[88]  W. L. Jorgensen,et al.  From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection , 2017, Proceedings of the National Academy of Sciences.

[89]  S. Pieraccini,et al.  In silico study of VP35 inhibitors: from computational alanine scanning to essential dynamics. , 2015, Molecular bioSystems.

[90]  Min-Sung Kim,et al.  Structure of HIV-1 reverse transcriptase cleaving RNA in an RNA/DNA hybrid , 2018, Proceedings of the National Academy of Sciences.

[91]  Youcef Mehellou,et al.  Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? , 2010, Journal of medicinal chemistry.

[92]  Y. Pommier,et al.  N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase. , 2015, Journal of medicinal chemistry.

[93]  Shigeru Miki,et al.  In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor , 2010, Antimicrobial Agents and Chemotherapy.

[94]  Maxwell D. Cummings,et al.  Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance , 2010, Proceedings of the National Academy of Sciences.

[95]  Stephen H Hughes,et al.  Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors , 2017, Journal of medicinal chemistry.

[96]  L. Menéndez-Arias.  Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. , 2013, Antiviral research.

[97]  N. Obel,et al.  Incidence, clinical presentation, and outcome of HIV-1-associated cryptococcal meningitis during the highly active antiretroviral therapy era: a nationwide cohort study , 2017, Clinical epidemiology.

[98]  Weiwei Xue,et al.  Molecular mechanism of HIV‐1 integrase–vDNA interactions and strand transfer inhibitor action: A molecular modeling perspective , 2012, J. Comput. Chem..

[99]  E. Garvey,et al.  Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). , 2013, Journal of medicinal chemistry.

[100]  F. Bailly,et al.  Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. , 2008, Journal of medicinal chemistry.

[101]  Jennifer C. Brookes,et al.  Unravelling the Molecular Basis of High Affinity Nanobodies against HIV p24: In Vitro Functional, Structural, and in Silico Insights. , 2017, ACS infectious diseases.

[102]  Y. Pommier,et al.  Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain. , 2015, Journal of medicinal chemistry.

[103]  E. Clercq,et al.  Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. , 2009, International journal of antimicrobial agents.

[104]  N. Sluis-Cremer,et al.  Mutational Analysis of Tyr-501 of HIV-1 Reverse Transcriptase , 2002, The Journal of Biological Chemistry.

[105]  B. Kirtman,et al.  Efficient vector potential method for calculating electronic and nuclear response of infinite periodic systems to finite electric fields. , 2007, The Journal of chemical physics.

[106]  M. Egger,et al.  Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: A mathematical modelling study , 2017, PLoS medicine.

[107]  Feng Xu,et al.  Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. , 2015, Pharmacological research.

[108]  R. Shafer.  Rationale and uses of a public HIV drug-resistance database. , 2006, The Journal of infectious diseases.

[109]  Feng Zhu,et al.  Exploring the Binding Mechanism of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators in Clinical Trials by Molecular Dynamics Simulations. , 2018, ACS chemical neuroscience.

[110]  M. Kvaratskhelia,et al.  HIV-1 integrase multimerization as a therapeutic target. , 2015, Current topics in microbiology and immunology.

[111]  Huanxiang Liu,et al.  Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598. , 2014, Antiviral research.